These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 20371718

  • 1. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N.
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [Abstract] [Full Text] [Related]

  • 2. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.
    Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2009 Dec 01; 69(23):8967-76. PubMed ID: 19920197
    [Abstract] [Full Text] [Related]

  • 3. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y, Yan H, Frost P, Gera J, Lichtenstein A.
    Mol Cancer Ther; 2005 Oct 01; 4(10):1533-40. PubMed ID: 16227402
    [Abstract] [Full Text] [Related]

  • 4. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
    Meng H, Jin Y, Liu H, You L, Yang C, Yang X, Qian W.
    J Hematol Oncol; 2013 Feb 18; 6():18. PubMed ID: 23415012
    [Abstract] [Full Text] [Related]

  • 5. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
    Mallon R, Hollander I, Feldberg L, Lucas J, Soloveva V, Venkatesan A, Dehnhardt C, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Gibbons J.
    Mol Cancer Ther; 2010 Apr 18; 9(4):976-84. PubMed ID: 20371716
    [Abstract] [Full Text] [Related]

  • 6. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
    Liu D, Hou P, Liu Z, Wu G, Xing M.
    Cancer Res; 2009 Sep 15; 69(18):7311-9. PubMed ID: 19706758
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
    Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC.
    Br J Haematol; 2007 Sep 15; 138(6):783-91. PubMed ID: 17760810
    [Abstract] [Full Text] [Related]

  • 8. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
    Li Y, Yang DQ.
    Mol Cancer Ther; 2010 Jan 15; 9(1):113-25. PubMed ID: 20053781
    [Abstract] [Full Text] [Related]

  • 9. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
    Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D.
    Mol Cancer Ther; 2009 May 15; 8(5):1157-68. PubMed ID: 19417153
    [Abstract] [Full Text] [Related]

  • 10. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
    Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B.
    Blood; 2010 Jun 03; 115(22):4455-63. PubMed ID: 20299510
    [Abstract] [Full Text] [Related]

  • 11. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
    Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC.
    Blood; 2006 May 15; 107(10):4053-62. PubMed ID: 16418332
    [Abstract] [Full Text] [Related]

  • 12. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R.
    Endocrinology; 2013 Mar 31; 154(3):1247-59. PubMed ID: 23384836
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of Prostate Cancer DU-145 Cells Proliferation by Anthopleura anjunae Oligopeptide (YVPGP) via PI3K/AKT/mTOR Signaling Pathway.
    Li X, Tang Y, Yu F, Sun Y, Huang F, Chen Y, Yang Z, Ding G.
    Mar Drugs; 2018 Sep 11; 16(9):. PubMed ID: 30208576
    [Abstract] [Full Text] [Related]

  • 17. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.
    Cancer Res; 2009 Jul 15; 69(14):5835-42. PubMed ID: 19584292
    [Abstract] [Full Text] [Related]

  • 18. The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.
    Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR, Sun SY.
    Mol Cancer Ther; 2007 Jul 15; 6(7):2029-38. PubMed ID: 17604333
    [Abstract] [Full Text] [Related]

  • 19. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
    Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, Rajkumar SV, Kumar S.
    PLoS One; 2012 Jul 15; 7(11):e50005. PubMed ID: 23185517
    [Abstract] [Full Text] [Related]

  • 20. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
    Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S.
    Cancer Res; 2005 Apr 15; 65(8):3336-46. PubMed ID: 15833867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.